Cervical cancer prevention: Better tests, better tools, and more equitable outcomes

Journal of the National Cancer Institute

Volumn 103, Issue 18, 2011, Pages 1352-1353

  Ault, Kevin A ^a  

^a EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

WART VIRUS VACCINE;

CANCER MORTALITY; CANCER PREVENTION; CANCER RISK; CANCER SCREENING; DIAGNOSTIC ACCURACY; DIAGNOSTIC TEST; FEMALE; GENOTYPE; HUMAN; NOTE; OUTCOME ASSESSMENT; PAPANICOLAOU TEST; PERSISTENT VIRUS INFECTION; PRIORITY JOURNAL; UTERINE CERVIX CANCER; UTERINE CERVIX DYSPLASIA; VIRUS DETECTION; VIRUS ONCOGENE; WART VIRUS;

ALPHAPAPILLOMAVIRUS; FEMALE; HUMANS; PAPILLOMAVIRUS INFECTIONS; TUMOR VIRUS INFECTIONS; UTERINE CERVICAL NEOPLASMS;

EID: 80053241309     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djr330     Document Type: Note

References (8)

1. Papanicolaou G, Traut H. The diagnostic value of vaginal smears in carcinoma of the uterus. Am J Obstet Gynecol. 1941;42(2):193-206.
2. Sankaranarayanan R, Nene B, Shastri S, et al. HPV screening for cervical cancer in rural India. New Engl J Med. 2009;360(14):1385-1394.
3. Chen H-C, Schiffman M, Lin C-Y, et al.; for the CBCSP-HPV Study Group. Persistence of type-specific human papillomavirus infection and increased long-term risk of cervical cancer. J Natl Cancer Inst. 2011;103(18):1387-1396.
4. Goldie SJ, Daniels M. Model-based analyses to compare health and economic outcomes of cancer control: inclusion of disparities. J Natl Cancer Inst. 2011;103(18):1373-1386.
5. Goldhaber-Fiebert JD, Stout NK, Ortendahl J, Kuntz KM, Goldie SJ, Salomon JA. Modeling human papillomavirus and cervical cancer in the United States for analyses of screening and vaccination. Popul Health Metr. 2007;5(1):11. http://www.pophealthmetrics.com/content/5/1/11. Accessed July 21, 2011.
6. Ault K; the FUTURE II Study Group. Prophylactic use of human papillomavirus (HPV) L1 virus-like particle vaccine significantly reduces cervical intraepithelial neoplasia grade 2, grade 3, and adenocarcinoma in situ risk: a combined analysis of four efficacy trials. Lancet. 2007;369(9576):1861- 1868. (Pubitemid 46829356)
7. Munoz N, Kjaer SK, Sigurdsson K, et al. Impact of human papillomavirus (HPV)-6/11/16/18 vaccine on all HPV-associated genital diseases in young women. J Natl Cancer Inst. 2010;102(5):325-339.
8. Brotherton J, Fridman M, May C, et al. Early effect of the HPV vaccination programme on cervical abnormalities in Victoria, Australia: an ecological study. Lancet. 2011;377(9783):2085-2092.